Pharmaceuticals - Top 5 Emerging Markets Industry Guide

NEW YORK, Jan. 7, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Pharmaceuticals - Top 5 Emerging Markets Industry Guide

http://www.reportlinker.com/p0191854/Pharmaceuticals---Top-5-Emerging-Markets-Industry-Guide.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pharmaceutical

Pharmaceuticals - Top 5 Emerging Markets Industry Guide is an essential resource for top-level data and analysis covering the Pharmaceuticals industry in each of the Top 5 Emerging markets (Brazil, China, India, Mexico and South Africa). The report includes easily comparable data on market value, volume, segmentation and market share, plus full five year market forecasts. It examines future problems, innovations and potential growth areas within the market.

Scope of the Report

* Contains an executive summary and data on value, volume and segmentation

* Provides textual analysis of the industry's prospects, competitive landscape and profiles of the leading companies

* Incorporates in-depth five forces competitive environment analysis and scorecards

* Compares data from Brazil, China, India, Mexico and South Africa, alongside individual chapters on each country. .

* Includes a five-year forecast of the industry

Highlights

The top 5 emerging countries contributed $101.8 billion to the global pharmaceuticals industry in 2011, with a compound annual growth rate (CAGR) of 15.5% between 2007 and 2011. The top 5 emerging countries are expected to reach a value of $185.3 billion in 2016, with a CAGR of 12.7% over the 2011-16 period.

Within the pharmaceuticals industry, China is the leading country among the top 5 emerging nations, with market revenues of $55.4 billion in 2011.

China is expected to lead the pharmaceuticals industry in the top five emerging nations, with a value of $108.1 billion in 2016, followed by Brazil and India with expected values of $29.0 and $27.3 billion, respectively.

Why you should buy this report * Spot future trends and developments

* Inform your business decisions

* Add weight to presentations and marketing materials

* Save time carrying out entry-level research

Market Definition

The pharmaceuticals market consists of ethical drugs only and does not include consumer healthcare or animal healthcare. Market values have been calculated at ex-factory prices (the value at which manufacturers sell the drugs to distributors). Any currency conversions used in the production of this report have been calculated at constant 2011 annual average exchange rates.TABLE OF CONTENTSIntroduction 11What is this report about? 11Who is the target reader? 11How to use this report 11Definitions 11Top 5 Emerging Countires Pharmaceuticals Industry Outlook 12Pharmaceuticals in South Africa 15Market Overview 15Market Data 16Market Segmentation 17Market outlook 19Five forces analysis 20Leading companies 28Macroeconomic indicators 38Pharmaceuticals in Brazil 40Market Overview 40Market Data 41Market Segmentation 42Market outlook 44Five forces analysis 45Leading companies 53Macroeconomic indicators 59Pharmaceuticals in China 61Market Overview 61Market Data 62Market Segmentation 63Market outlook 65Five forces analysis 66Leading companies 74Macroeconomic indicators 82Pharmaceuticals in India 84Market Overview 84Market Data 85Market Segmentation 86Market outlook 88Five forces analysis 89Leading companies 97Macroeconomic indicators 110Pharmaceuticals in Mexico 112Market Overview 112Market Data 113Market Segmentation 114Market outlook 116Five forces analysis 117Leading companies 125Macroeconomic indicators 135Appendix 137Methodology 137

LIST OF TABLES

Table 1: Top 5 emerging countries pharmaceuticals industry, revenue ($bn), 2007-16 12

Table 2: Top 5 emerging countries pharmaceuticals industry, revenue ($bn), 2007-11 13

Table 3: Top 5 emerging countries pharmaceuticals industry forecast, revenue ($bn), 2011-16 14

Table 4: South Africa pharmaceuticals market value: $ billion, 2007–11 16

Table 5: South Africa pharmaceuticals market geography segmentation: $ million, 2007–2011 17

Table 6: South Africa pharmaceuticals market share: % share, by value, 2011 18

Table 7: South Africa pharmaceuticals market value forecast: $ billion, 2011–16 19

Table 8: Pfizer Inc.: key facts 28

Table 9: Pfizer Inc.: key financials ($) 29

Table 10: Pfizer Inc.: key financial ratios 29

Table 11: GlaxoSmithKline Plc: key facts 31

Table 12: GlaxoSmithKline Plc: key financials ($) 32

Table 13: GlaxoSmithKline Plc: key financials (£) 33

Table 14: GlaxoSmithKline Plc: key financial ratios 33

Table 15: Aspen Pharmacare Holdings Ltd: key facts 35

Table 16: Aspen Pharmacare Holdings Ltd: key financials ($) 36

Table 17: Aspen Pharmacare Holdings Ltd: key financials (ZAR) 36

Table 18: Aspen Pharmacare Holdings Ltd: key financial ratios 36

Table 19: South Africa size of population (million), 2007–11 38

Table 20: South Africa gdp (constant 2000 prices, $ billion), 2007–11 38

Table 21: South Africa gdp (current prices, $ billion), 2007–11 38

Table 22: South Africa inflation, 2007–11 39

Table 23: South Africa consumer price index (absolute), 2007–11 39

Table 24: South Africa exchange rate, 2007–11 39

Table 25: Brazil pharmaceuticals market value: $ billion, 2007–11 41

Table 26: Brazil pharmaceuticals market geography segmentation: $ billion, 2011 42

Table 27: Brazil pharmaceuticals market share: % share, by value, 2011 43

Table 28: Brazil pharmaceuticals market value forecast: $ billion, 2011–16 44

Table 29: Aché Laboratórios Farmacêuticos S.A.: key facts 53

Table 30: Medley Indústria Farmacêutica Ltd: key facts 54

Table 31: Sanofi: key facts 55

Table 32: Sanofi: key financials ($) 56

Table 33: Sanofi: key financials (€) 56

Table 34: Sanofi: key financial ratios 56

Table 35: EMS Sigma Pharma: key facts 58

Table 36: Brazil size of population (million), 2007–11 59

Table 37: Brazil gdp (constant 2000 prices, $ billion), 2007–11 59

Table 38: Brazil gdp (current prices, $ billion), 2007–11 59

Table 39: Brazil inflation, 2007–11 60

Table 40: Brazil consumer price index (absolute), 2007–11 60

Table 41: Brazil exchange rate, 2007–11 60

Table 42: China pharmaceuticals market value: $ billion, 2007–11 62

Table 43: China pharmaceuticals market geography segmentation: $ billion, 2011 63

Table 44: China pharmaceuticals market share: % share, by value, 2011 64

Table 45: China pharmaceuticals market value forecast: $ billion, 2011–16 65

Table 46: Pfizer Inc.: key facts 74

Table 47: Pfizer Inc.: key financials ($) 75

Table 48: Pfizer Inc.: key financial ratios 75

Table 49: AstraZeneca PLC: key facts 77

Table 50: AstraZeneca PLC: key financials ($) 78

Table 51: AstraZeneca PLC: key financial ratios 79

Table 52: Jiangsu Yangtze River Pharmaceutical Group Company Ltd.: key facts 81

Table 53: China size of population (million), 2007–11 82

Table 54: China gdp (constant 2000 prices, $ billion), 2007–11 82

Table 55: China gdp (current prices, $ billion), 2007–11 82

Table 56: China inflation, 2007–11 83

Table 57: China consumer price index (absolute), 2007–11 83

Table 58: China exchange rate, 2007–11 83

Table 59: India pharmaceuticals market value: $ billion, 2007–11 85

Table 60: India pharmaceuticals market geography segmentation: $ billion, 2011 86

Table 61: India pharmaceuticals market share: % share, by value, 2011 87

Table 62: India pharmaceuticals market value forecast: $ billion, 2011–16 88

Table 63: Dr. Reddy's Laboratories Limited: key facts 97

Table 64: Dr. Reddy's Laboratories Limited: key financials ($) 98

Table 65: Dr. Reddy's Laboratories Limited: key financials (Rs.) 98

Table 66: Dr. Reddy's Laboratories Limited: key financial ratios 98

Table 67: Cipla Limited: key facts 100

Table 68: Cipla Limited: key financials ($) 101

Table 69: Cipla Limited: key financials (Rs.) 101

Table 70: Cipla Limited: key financial ratios 101

Table 71: Ranbaxy Laboratories Limited: key facts 103

Table 72: Ranbaxy Laboratories Limited: key financials ($) 104

Table 73: Ranbaxy Laboratories Limited: key financials (Rs.) 104

Table 74: Ranbaxy Laboratories Limited: key financial ratios 104

Table 75: Lupin Limited: key facts 106

Table 76: Lupin Limited: key financials ($) 107

Table 77: Lupin Limited: key financials (Rs.) 107

Table 78: Lupin Limited: key financial ratios 108

Table 79: India size of population (million), 2007–11 110

Table 80: India gdp (constant 2000 prices, $ billion), 2007–11 110

Table 81: India gdp (current prices, $ billion), 2007–11 110

Table 82: India inflation, 2007–11 111

Table 83: India consumer price index (absolute), 2007–11 111

Table 84: India exchange rate, 2007–11 111

Table 85: Mexico pharmaceuticals market value: $ billion, 2007–11 113

Table 86: Mexico pharmaceuticals market geography segmentation: $ billion, 2011 114

Table 87: Mexico pharmaceuticals market share: % share, by value, 2011 115

Table 88: Mexico pharmaceuticals market value forecast: $ billion, 2011–16 116

Table 89: Eli Lilly and Company: key facts 125

Table 90: Eli Lilly and Company: key financials ($) 126

Table 91: Eli Lilly and Company: key financial ratios 126

Table 92: Pfizer Inc.: key facts 128

Table 93: Pfizer Inc.: key financials ($) 129

Table 94: Pfizer Inc.: key financial ratios 129

Table 95: GlaxoSmithKline Plc: key facts 131

Table 96: GlaxoSmithKline Plc: key financials ($) 132

Table 97: GlaxoSmithKline Plc: key financials (£) 133

Table 98: GlaxoSmithKline Plc: key financial ratios 133

Table 99: Mexico size of population (million), 2007–11 135

Table 100: Mexico gdp (constant 2000 prices, $ billion), 2007–11 135

Table 101: Mexico gdp (current prices, $ billion), 2007–11 135

Table 102: Mexico inflation, 2007–11 136

Table 103: Mexico consumer price index (absolute), 2007–11 136

Table 104: Mexico exchange rate, 2007–11 136

LIST OF FIGURES

Figure 1: South Africa pharmaceuticals market value: $ billion, 2007–11 16Figure 2: South Africa pharmaceuticals market geography segmentation: % share, by value, 2007,2011 17Figure 3: South Africa pharmaceuticals market share: % share, by value, 2011 18Figure 4: South Africa pharmaceuticals market value forecast: $ billion, 2011–16 19Figure 5: Forces driving competition in the pharmaceuticals market in South Africa, 2011 20Figure 6: Drivers of buyer power in the pharmaceuticals market in South Africa, 2011 21Figure 7: Drivers of supplier power in the pharmaceuticals market in South Africa, 2011 23Figure 8: Factors influencing the likelihood of new entrants in the pharmaceuticals market in South Africa, 2011 24Figure 9: Factors influencing the threat of substitutes in the pharmaceuticals market in South Africa, 2011 26Figure 10: Drivers of degree of rivalry in the pharmaceuticals market in South Africa, 2011 27Figure 11: Pfizer Inc.: revenues & profitability 30Figure 12: Pfizer Inc.: assets & liabilities 30Figure 13: GlaxoSmithKline Plc: revenues & profitability 33Figure 14: GlaxoSmithKline Plc: assets & liabilities 34Figure 15: Aspen Pharmacare Holdings Ltd: revenues & profitability 37Figure 16: Aspen Pharmacare Holdings Ltd: assets & liabilities 37Figure 17: Brazil pharmaceuticals market value: $ billion, 2007–11 41Figure 18: Brazil pharmaceuticals market geography segmentation: % share, by value, 2011 42Figure 19: Brazil pharmaceuticals market share: % share, by value, 2011 43Figure 20: Brazil pharmaceuticals market value forecast: $ billion, 2011–16 44Figure 21: Forces driving competition in the pharmaceuticals market in Brazil, 2011 45Figure 22: Drivers of buyer power in the pharmaceuticals market in Brazil, 2011 46Figure 23: Drivers of supplier power in the pharmaceuticals market in Brazil, 2011 48Figure 24: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Brazil, 2011 49Figure 25: Factors influencing the threat of substitutes in the pharmaceuticals market in Brazil, 2011 51Figure 26: Drivers of degree of rivalry in the pharmaceuticals market in Brazil, 2011 52Figure 27: Sanofi: revenues & profitability 57Figure 28: Sanofi: assets & liabilities 57Figure 29: China pharmaceuticals market value: $ billion, 2007–11 62Figure 30: China pharmaceuticals market geography segmentation: % share, by value, 2011 63Figure 31: China pharmaceuticals market share: % share, by value, 2011 64Figure 32: China pharmaceuticals market value forecast: $ billion, 2011–16 65Figure 33: Forces driving competition in the pharmaceuticals market in China, 2011 66Figure 34: Drivers of buyer power in the pharmaceuticals market in China, 2011 67Figure 35: Drivers of supplier power in the pharmaceuticals market in China, 2011 69Figure 36: Factors influencing the likelihood of new entrants in the pharmaceuticals market in China, 2011 70Figure 37: Factors influencing the threat of substitutes in the pharmaceuticals market in China, 2011 72Figure 38: Drivers of degree of rivalry in the pharmaceuticals market in China, 2011 73Figure 39: Pfizer Inc.: revenues & profitability 76Figure 40: Pfizer Inc.: assets & liabilities 76Figure 41: AstraZeneca PLC: revenues & profitability 79Figure 42: AstraZeneca PLC: assets & liabilities 80Figure 43: India pharmaceuticals market value: $ billion, 2007–11 85Figure 44: India pharmaceuticals market geography segmentation: % share, by value, 2011 86Figure 45: India pharmaceuticals market share: % share, by value, 2011 87Figure 46: India pharmaceuticals market value forecast: $ billion, 2011–16 88Figure 47: Forces driving competition in the pharmaceuticals market in India, 2011 89Figure 48: Drivers of buyer power in the pharmaceuticals market in India, 2011 90Figure 49: Drivers of supplier power in the pharmaceuticals market in India, 2011 92Figure 50: Factors influencing the likelihood of new entrants in the pharmaceuticals market in India, 2011 93Figure 51: Factors influencing the threat of substitutes in the pharmaceuticals market in India, 2011 95Figure 52: Drivers of degree of rivalry in the pharmaceuticals market in India, 2011 96Figure 53: Dr. Reddy's Laboratories Limited: revenues & profitability 99Figure 54: Dr. Reddy's Laboratories Limited: assets & liabilities 99Figure 55: Cipla Limited: revenues & profitability 102Figure 56: Cipla Limited: assets & liabilities 102Figure 57: Ranbaxy Laboratories Limited: revenues & profitability 105Figure 58: Ranbaxy Laboratories Limited: assets & liabilities 105Figure 59: Lupin Limited: revenues & profitability 108Figure 60: Lupin Limited: assets & liabilities 109Figure 61: Mexico pharmaceuticals market value: $ billion, 2007–11 113Figure 62: Mexico pharmaceuticals market geography segmentation: % share, by value, 2011 114Figure 63: Mexico pharmaceuticals market share: % share, by value, 2011 115Figure 64: Mexico pharmaceuticals market value forecast: $ billion, 2011–16 116Figure 65: Forces driving competition in the pharmaceuticals market in Mexico, 2011 117Figure 66: Drivers of buyer power in the pharmaceuticals market in Mexico, 2011 118Figure 67: Drivers of supplier power in the pharmaceuticals market in Mexico, 2011 120Figure 68: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Mexico, 2011 121Figure 69: Factors influencing the threat of substitutes in the pharmaceuticals market in Mexico, 2011 123Figure 70: Drivers of degree of rivalry in the pharmaceuticals market in Mexico, 2011 124Figure 71: Eli Lilly and Company: revenues & profitability 127Figure 72: Eli Lilly and Company: assets & liabilities 127Figure 73: Pfizer Inc.: revenues & profitability 130Figure 74: Pfizer Inc.: assets & liabilities 130Figure 75: GlaxoSmithKline Plc: revenues & profitability 133Figure 76: GlaxoSmithKline Plc: assets & liabilities 134

To order this report:Pharmaceutical Industry: Pharmaceuticals - Top 5 Emerging Markets Industry Guide

CONTACT
Reportlinker
Email: nicolasbombourg@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker



RELATED LINKS
http://www.reportlinker.com

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.